Emerging evidence suggests that the hypocretinergic system is involved in addictive behavior. In this study, we investigated the role of these hypothalamic neuropeptides in anxiety-like responses of nicotine and stress-induced reinstatement of nicotine-seeking behavior. Acute nicotine (0.8 mg/kg, s.c.) induced anxiogenic-like effects in the elevated plus-maze and activated the paraventricular nucleus of the hypothalamus (PVN) as revealed by c-Fos expression. Pretreatment with the hypocretin receptor 1 (Hcrt-1) antagonist SB334867 or preprohypocretin gene deletion blocked both nicotine effects. In the PVN, SB334867 also prevented the activation of corticotrophin releasing factor (CRF) and arginine-vasopressin (AVP) neurons, which expressed Hcrt-r-1. In addition, an increase of the percentage of c-Fos-positive hypocretin cells in the perifornical and dorsomedial hypothalamic (PFA/DMH) areas was found after nicotine (0.8 mg/kg, s.c.) administration. Intracerebroventricular infusion of hypocretin-1 (Hcrt-1) (0.75 nmol/1 μl) or footshock stress reinstated a previously extinguished nicotine-seeking behavior. The effects of Hcrt-1 were blocked by SB334867, but not by the CRF1 receptor antagonist antalarmin. Moreover, SB334867 did not block CRF-dependent footshock-induced reinstatement of nicotine-seeking while antalarmin was effective in preventing this nicotine motivational response. Therefore, the Hcrt system interacts with CRF and AVP neurons in the PVN and modulates the anxiogenic-like effects of nicotine whereas Hcrt and CRF play a different role in the reinstatement of nicotine-seeking. Indeed, Hcrt-1 reinstates nicotine-seeking through a mechanism independent of CRF activation whereas CRF mediates the reinstatement induced by stress.

Introduction

Tobacco smoking is a major public health problem worldwide characterized by loss of control over tobacco consumption despite the harmful effects, the appearance of withdrawal symptoms upon smoking cessation, and relapse after periods of abstinence (McLellan et al., 2000). Once cessation of use has been established, preventing relapse is the main objective of the treatment. Stress has been shown to increase vulnerability and cause relapse to nicotine-seeking behavior in humans (Cohen and Lichtenstein, 1990), and animal models (Bilkei-Gorzo et al., 2008; Martín-García et al., 2009). Human and animal studies have also revealed that nicotine modifies anxiety-like behavior, which could participate in its addictive properties. Smokers report that tobacco consumption decreases anxiety and alleviates stress (Pomerleau, 1986; Kassel and Unrod, 2000), although other studies have reported that nicotine can also increase levels of anxiety (Newhouse et al., 1990; Foulds et al., 1997). In agreement with the possible anxiolytic-like effects of nicotine, smokers display higher scores in anxiety-related tests than nonsmokers (Parrott, 1995). According to human studies, several reports have shown that nicotine induces anxiogenic- or anxiolytic-like responses in rodents depending on the dose, the route of administration, the genetic strain and the baseline anxiety level (File et al., 2000; Balerio et al., 2005). The neurobiological mechanisms underlying the effects of nicotine on anxiety and stress remain to be clarified.

Hypocretin-1 and 2 (Hcrt-1 and Hcrt-2), also known as orexin A and B, are neuropeptides produced exclusively in neurons of the lateral hypothalamus and contiguous perifornical area (de Lecea et al., 1998; Sakurai et al., 1998) that project widely through the brain (Peyron et al., 1998). These peptides produce their physiological effects acting on two G-protein coupled receptors, hypocretin receptors 1 and 2 (Hcrt-1 and Hcrt-2) (de Lecea et al., 1998; Sakurai et al., 1998). Hcrt-1 binds to both receptors with similar affinity, whereas Hcrt-2 binds to Hcrt-2 with tenfold greater affinity than to Hcrt-1. The hypocretinergic system was initially involved in the regulation of food intake, energy metabolism and the maintenance of arousal (Harris and Aston-Jones, 2006). However, recent studies have demonstrated that hypocretins take part in reward processing and addiction (Aston-Jones et al., 2009; Sharif et al., 2009). Thus, Hcrt transmission participates in morphine (Narita et al.,
2006), ethanol (Lawrence et al., 2006) and nicotine (Hollander et al., 2008) rewarding properties. In addition, Hcrt-containing neurons are sensitive and can also regulate the activity of arousal-promoting transmitters, including the corticotrophin releasing factor (CRF), a peptide involved in stress responses (Winsky-Sommerer et al., 2004). The increased activity of Hcrt leads to a state of hyperarousal that could contribute to the vulnerability to relapse for drug seeking (de Lecea et al., 2006). In agreement, Hcrt-1 blockade attenuates stress-induced reinstatement of extinguished cocaine (Boutrel et al., 2005) and alcohol (Richards et al., 2008) seeking.

This study was undertaken to investigate whether the Hcrt system regulates the behavioral and biochemical processes underlying nicotine-induced anxiety-like responses and the reinstatement of nicotine-seeking behavior. The specific involvement of the CRF system in the effects of Hcrt transmission on these two behavioral responses related to nicotine addiction was also evaluated.

Materials and Methods

**Animals**

Experiments were performed in male C57BL/6J mice (Charles River) and in male preprohypocretin knock-out (KO) and their wild-type C57BL/6J mice (8–10 weeks old). Generation of mice with a deletion of the preprohypocretin gene has been previously described (Chemelli et al., 1999). These mice do not produce either of the Hcrt-1 or Hcrt-2 peptides and have been extensively characterized at the behavioral level. Thus, KO mice display fragmented sleep and behavioral arrests reminiscent of cataplexy during the dark period, but otherwise normal sleep homeostasis (Plaza-Zabala et al., 2004). Under ad libitum conditions, feeding and drinking patterns are also normal. Preprohypocretin KO mice were back-crossed for 9 generations into C57BL/6J, and genotyped as described previously (Chemelli et al., 1999). Mice were housed five per cage in a temperature (21 ± 1°C)- and humidity (55 ± 10%)-controlled room. For the reinstatement study, mice were single housed and exposed to a reversed 12 h light/dark cycle (lights off 8:00 A.M.) and the experiments took place during the dark phase. These mice were habituated to the reversed cycle conditions for 1 week before starting the nicotine self-administration sessions. For the other experiments, mice were exposed to a normal cycle (lights on 8:00 A.M.) and the experiments took place in the light phase. Food and water were available ad libitum except during the exposure to the different behavioral paradigms. Mice were habituated to their new environment and handled for 1 week after arrival, and before starting the experimental procedure. The observer was blind to treatment in all the experiments. Animal procedures were conducted in accordance with the guidelines of the European Communities Directive 86/609/EEC regulating animal research and approved by the local ethical committee (CEEA-IMAS-UPF).

**Drugs**

(–)-Nicotine hydrogen tartrate salt [(–)-1-methyl-2(3-pyridyl)pyrrolidine] (Sigma) was dissolved in physiological saline (0.9% NaCl) and administered by subcutaneous route in a volume of 10 ml/kg body weight. For the self-administration study, the pH of nicotine solution was adjusted to 7.4 and was contingently administered by intravenous route. All nicotine doses were calculated as nicotine hydrogen tartrate salt. SB334867 (Tocris Bioscience) was dissolved in 1% (2-hydroxypropyl)-β-cyclodextrin (Sigma) and 10% DMSO in 90% distilled water and administered by intraperitoneal route in a volume of 5 ml/kg body weight at the doses of 5 and 10 mg/kg. The SB334867 doses were based on previous studies (Rodgers et al., 2001) and a pilot experiment testing the effects of this antagonist on the hyperactivity induced by Hcrt-1 in C57BL/6J mice (supplemental Fig. 1, available at www.jneurosci.org as supplemental material). Hcrt-1 and colchicine (Sigma) were dissolved in physiological saline and administered by intracerebroventricular route. Antalarmin was dissolved in cremophor/ethanol at 2:1 and was administered subcutaneously in a volume of 10 ml/kg body weight at the dose of 30 mg/kg (Pañeda et al., 2009). Ketamine hydrochloride (100 mg/kg) (Imalgene 1000) and xylazine hydrochloride (20 mg/kg) (Sigma) were mixed and dissolved in ethanol (5%) and distilled water (95%). This anesthetic mixture was administered intraperitoneally in a volume of 10 ml/kg body weight. Thiopental sodium (5 mg/ml) (Braun Medical S.A.) was dissolved in distilled water and delivered through the intravenous catheter.

**Cannulation and intracerebroventricular infusions**

Colchicine and Hcrt-1 were infused intracerebroventricularly for CRF and arginine-vasopressin (AVP) immunodetection and the reinstatement study, respectively. Mice were anesthetized with a ketamine/xylazine mixture and mounted on a stereotaxic apparatus with a flat skull (Paxinos and Franklin, 1997). A small hole was drilled on the left or the right side of the skull randomly and the cannula (30 gauge, 10 mm long) was implanted vertically into the left/right lateral ventricle at the following coordinates relative to bregma according to the atlas of Paxinos and Franklin (1997): anteroposterior, −0.22 mm; mediolateral, +1.00/−1.00 mm; and dorsoventral, −2.25 mm. The cannula was fixed to the skull with dental cement. Mice were then housed individually and allowed 1 additional day for handling. Drugs were infused into the lateral ventricle of freely moving mice by connecting the cannula to polyethylene tubing (inner diameter, 0.28 mm; outer diameter, 0.61 mm) attached to a 10 μl Hamilton micro syringe at a constant rate of 1 ml/min during 1 min using a multiple micro syringe driven pump (Harvard 22, Harvard Apparatus). Polyethylene tubing was removed from the cannula 1 min after infusions to prevent drug reflux. 0.05% methylene blue solution (Sigma) was perfused under the same experimental conditions to check the correct position of the cannula at the end of the experiment.

**Acute behavioral tests**

Pharmacological (SB334867 administration) and genetic (preprohypocretin KO mice) approaches were used in this set of experiments. For the pharmacological studies, mice received an injection of SB334867 (5 mg/kg, i.p.) or vehicle 30 min before the acute administration of nicotine or saline.

The changes in horizontal locomotor activity induced by acute administration of nicotine (1, 3, and 6 mg/kg, s.c.) or saline were measured by using individual locomotor activity boxes (9 × 20 × 11 cm, Imetronic), as previously described (Berrendero et al., 2005). Mice were placed in the locomotor cages 5 min after drug injection, and activity was recorded for 10 min in a low luminosity environment (20–25 lux). The antinoceptive responses for each mouse were determined 15 and 16 min after nicotine (1, 3, and 6 mg/kg, s.c.) or saline administration using the tail-immersion and the hot-plate test respectively, as previously reported (Berrendero et al., 2005). In the tail-immersion test, the latency to a rapid flick of the tail was taken as the endpoint, and the maximum latency allowed was 5 s. The threshold evaluated was the jumping response in the hot-plate test. In absence of jumps, a 240 s cutoff was used to prevent tissue damage. The data obtained were expressed as percentage of maximum possible effect (MPE) using the following equation: % MPE = [(test latency − control latency)/(cutoff time − control latency)] × 100.

The effects of nicotine (0.05 and 0.8 mg/kg, s.c.) on anxiety-like responses were evaluated using the elevated plus-maze 5 min after nicotine or saline administration, as previously reported (Balero et al., 2005). Each mouse was placed in the central neutral area facing one of the open arms and observed during 5 min. Results are expressed as the percentage of time spent in the open arms.

**Immunofluorescence studies**

**Tissue preparation.** For CRF and AVP detection colchicine (7 μg/1 μl, i.c.v.) was injected 24 h before acute drug treatment. Blockade of axonal transport is essential for localization of significant CRF immunoreactivity in neuronal cell bodies. A low dose was selected to avoid c-Fos induction by colchicine itself (Valentine et al., 1996). One hour after nicotine challenge, mice were transcardially perfused with 4% paraformaldehyde (PFA), postfixed in the same fixative for 4 h (4°C) and cryoprotected overnight in a solution of 30% sucrose at 4°C. Coronal frozen sections were made at 30 μm on a freezing microtome and stored in a 5% sucrose solution at 4°C until use.
Immunoﬂuorescence. A previously described protocol (Balero et al., 2004) was adapted for immunoﬂuorescence. Sections were incubated with the primary antibody in 3% normal goat serum and 0.3% Triton X-100 in 0.1 M PBS (NGS-T-PB) overnight at 4°C (for the Hcrtr-1 detection the incubation was extended to 36 h). Next day, sections were incubated with the secondary antibody at room temperature in NGS-T-PB for 2 h. After incubation, sections were rinsed and mounted immediately after onto glass slides coated with gelatin in Mowiol mounting medium. For c-Fos and Hcrtr-1 detection a rabbit polyclonal antisem (1:1000) (Ab-5; Calbiochem) and a mouse monoclonal antibody (1:500) (R&D Systems) were used respectively. Guinea-pig polyclonal antibodies (1:1000) (Peninsula Laboratories) were used for CRF and AVP detection. For the Hcrtr-1 detection rabbit polyclonal antibody (1:500) (Alpha Diagnostics) was used. As secondary antibodies, Cy3-conjugated goat anti-rabbit and Cy2-conjugated goat anti-mouse and anti-guinea pig IgG (Jackson ImmunoResearch) were used (1:500).

C-Fos quantification. The stained sections of the brain were analyzed at 10× objective using a Leica DMR microscope equipped with a digital camera Leica DFC 300 FX. ImageJ software was used for the quantification of c-Fos-positive nuclei. Two samples of 3–5 mice per each group were quantiﬁed. Circular particles were analyzed in transformed binary images using a constant region of interest (ROI). The threshold was adjusted to distinguish the particles from the background.

Colocalization analysis. For the colocalization analysis of c-Fos or Hcrtr-1 with CRF/AVP and c-Fos with Hcrtr-1, the stained sections were analyzed at 40× objective with oil-immersion using a Leica SP2 confocal microscope adapted to an inverted Leica DM IRBE microscope. The quantification of CRF/AVP or Hcrtr-1-positive cells for c-Fos was done manually in 3–4 different samples of 3 mice.

Reinstatement of nicotine-seeking behavior Apparatus. The experiments were conducted in mouse operant chambers (model ENV-307-A-CT; Med Associates Inc.) equipped with two holes, one randomly selected as the active hole and the other as the inactive hole. Pump noise and stimuli lights (cues), one located inside the active hole and the other above it were paired with the delivery of the reinforcer. Nicotine (85.5 μg/kg per infusion) or saline was delivered in a volume of 23.5 μl over 2 s via a syringe that was mounted on a microinfusion pump and connected via Tygon tubing to a single channel liquid swivel and to the mouse intravenous catheter.

Jugular vein catheterization. Mice were anesthetized with a ketamine/xylazine mixture and then implanted with indwelling intravenous SILASTIC catheters on their right jugular vein as previously described (Soria et al., 2005). Briefly, a 6 cm length of SILASTIC tubing (0.3 mm inner diameter, 0.6 mm outer diameter) (SILASTIC, Dow Corning) was ﬁtted to a 22-gauge steel cannula (Semat) that was bent at a right angle and then embedded in a cement disk (Dentalon Plus, Heraeus) with an underlying nylon mesh. The catheter tubing was inserted 1.3 cm into the right jugular vein and anchored with suture. The remaining tubing ran subcutaneously to the cannula, which exited at the midscapular region. All incisions were sutured and coated with antibiotic ointment (Bactroban; GlaxoSmithKline). After surgery, animals were allowed to recover for 5 d before initiation of self-administration sessions.

Self-administration training. Slight modiﬁcations were done to the operant model recently described (Martín-García et al., 2009). One daily self-administration sessions were conducted consecutively for 10 d. Mice were trained under a ﬁxed ratio 1 (FR1) schedule of reinforcement with a 10 s time-out. Each daily session started with a priming injection of the drug. The stimuli light together with the pump noise (environmental cues) signaled delivery of nicotine infusion. During the 10 s time-out period, the cue light was off and no reward was provided after nose-poking on the active hole. Responses on the inactive hole and all the responses elicited during the 10 s time-out period were also recorded. The session was terminated after 50 reinforcers were delivered or after 1 h, whichever occurred ﬁrst. The criteria for the acquisition of self-administration behavior were achieved when in three consecutive sessions: (1) mice maintained a stable responding with ≤20% deviation from the mean of the total number of reinforcers earned (80% stability); (2) at least 75% responding on the active hole, and (3) a minimum of 6 reinforcers per session. The latency of intravenous catheters was evaluated at the end of nicotine self-administration training by an infusion of 0.05–0.1 ml of thiopental sodium through the catheter. If prominent signs of anesthesia were not apparent within 3 s of the infusion the mouse was removed from the experiment. Only animals with patent catheter that met all the acquisition criteria were moved to the extinction phase. Mice were divided in 2 groups depending on the reinstatement procedure. Animals selected for the footshock stress-induced reinstatement were allowed to rest for 1 d after the end of the self-administration training before the beginning of the extinction sessions. Animals selected to receive Hcrtr-1 in the lateral ventricle were cannulated 1 d after the end of the self-administration training and allowed to rest for one additional day before the beginning of the extinction sessions. Intracerebroventricular injections were performed after mice achieved the extinction criteria (average of 25 ± 2 daily sessions), when mice were completely recovered from the effects of surgery.

Extinction. During the extinction period, nicotine and cues were not available after nose-poking in the active hole. Mice were given 1 h daily sessions 7 d per week until reaching the extinction criterion during a maximum of 50 d. The criterion was achieved when responses on the active hole were <30% of the mean responses obtained during the 3 d achieving the acquisition criteria across 3 consecutive extinction sessions. Only animals that reached the extinction criterion were evaluated for nicotine reinstatement induced by Hcrtr-1 or footshock. Tests for reinstatement were conducted under the same conditions used in the extinction phase.

Hcrtr-1-induced reinstatement. The ﬁrst day after achieving the extinction criterion, mice received an intracerebroventricular vehicle infusion preceded by vehicle, SB334867 (5 mg/kg, i.p.) or antalarmin (30 mg/kg, s.c.). SB334867 and antalarmin were administered 30 min and 1 h before the intracerebroventricular infusions respectively, as previously reported (Boutrel et al., 2005; Pañeda et al., 2009). The next day, mice received an intracerebroventricular Hcrtr-1 (0.75 nmol/1 μl) infusion preceded by the same vehicle, SB334867 or antalarmin. Subsequently, mice were given extinction sessions until reaching the extinction criterion and were infused with an intracerebroventricular vehicle infusion to rule out any order effect on Hcrtr-1-induced reinstatement. Tests for reinstatement were conducted 10 min after the intracerebroventricular vehicle or Hcrtr-1 infusion. The dose selected for Hcrtr-1 infusion was based on previous studies (Boutrel et al., 2005; Nair et al., 2008).

Footshock stress-induced reinstatement. The group of mice exposed to footshock stress received intermittent footshock stimuli (5 footshocks separated by a 1 min period without shock) with an intensity of 0.22 mA during 5 min immediately before the reinstatement session, as previously reported (Martín-García et al., 2009). Mice were pretreated with SB334867 (5 and 10 mg/kg, i.p.), antalarmin (30 mg/kg, s.c.) or vehicle before applying the footshock. SB334867 and antalarmin were administered 30 min and 1 h before the footshock, respectively.

Operant conditioning maintained by water To discard any possible learning or memory impairment produced by the administration of the Hcrtr-1 antagonist SB334867 (5 mg/kg, i.p.) on operant conditioning, a different group of C57BL/6J mice were trained to acquire nose-poking operant behavior maintained by water. Slight modiﬁcations were done to the protocol previously described (Soria et al., 2005). Mice were ﬁrst deprived of water during 2 d (20 min of free water was provided daily) and this same water deprivation regime was maintained during the whole evaluation of water-maintained operant behavior. Food was available ad libitum during this experimental phase. Two days after starting water deprivation, mice were trained to nose-poke for water in the operant chambers. SB334867 or vehicle was administered 30 min before starting each session. One hour daily operant sessions were conducted 7 d per week during 10 d. The house light was turned off at the beginning of the session for 3 s and off during the remaining duration of the session. Operant responding maintained by water was conducted in the same operant chambers described above for nicotine self-administration experiments except that a liquid dipper was used instead of an infusion pump and operant nose-poking responses were maintained by
delivery of 10 μl of water over 10 s. Mice were trained under a fixed ratio 1 (FR1) schedule of reinforcement. A 20 s time-out period was established after each reinforcement. During this 20 s period, the cue light was off and no reward was provided on the active hole. Responses on the inactive hole and all the responses during the 20 s time-out period were also recorded. The session was terminated after 100 reinforcers were delivered or after 1 h, whichever occurred first. The criteria for the acquisition were achieved when in three consecutive sessions: (1) mice maintained a stable responding with <20% deviation from the mean of the total number of reinforcers earned (80% stability); (2) at least 75% responding on the active hole, and (3) a minimum of 10 reinforcers per session. Mice reaching these criteria were changed to a progressive ratio (PR) schedule of reinforcement on day 11, in which the response requirement to earn a reinforcer escalated according to the following series: 1–2–3–5–12–27–40–60–90–135–200–300–450–675–1000. The PR session lasted 4 h until mice did not complete the ratio for delivery of one reinforcer within 1 h, and was performed only once.

Statistical analysis
Two-way ANOVA was used to analyze the acute effects of nicotine on locomotor activity, antinociception and anxiety-like effects with SB334867 pretreatment/genotype and nicotine treatment as between-subject factors of variation. Subsequent one-way ANOVA and post hoc comparisons (Newman–Keuls) were used when required. The percentage of hypocretin cells expressing c-Fos in the perifornical and dorsomedial hypothalamic areas (PFA/DMH) as well as in the lateral hypothalamus (LH) after nicotine injection was analyzed by Student’s t test. To analyze the acquisition of nicotine self-administration, two-way ANOVA with repeated measures with the factors hole and day was used. The analysis was followed by one-way ANOVA for each day of training. Pearson’s χ² test was used to compare the percentage of acquisition between animals trained to self-administer nicotine and saline. To evaluate the reinstatement of nicotine-seeking behavior, animals were divided in different groups corresponding to each experimental condition used to induce reinstatement (Hcrt-1 administration or electric footshock in animals pretreated with vehicle, SB334867 or antalarmin). Two-way ANOVA with repeated measures with the factors hole and experimental phase followed by corresponding one-way ANOVA and post hoc analyses (Newman–Keuls) were performed when required. All the animals reaching the reinstatement phase were included in this analysis. The level of significance was p < 0.05 in all experiments.

Results
Hcrt neurons involve the anxiogenic-like effects of nicotine
Acute nicotine administration (0.8 mg/kg, s.c.) induces anxiogenic-like effects in the mouse elevated plus-maze (Balerio et al., 2005). We found that pretreatment with the Hcrt1 antagonist SB334867 and preprohypocretin gene deletion blocked the anxiogenic-like effects of nicotine (Fig. 1A, B). Two-way ANOVA for the percentage of time spent in the open arms showed a significant interaction between SB334867 pretreatment and nicotine treatment (F(1,63) = 6.50, p < 0.05). Subsequent one-way ANOVA showed a blockade of the anxiogenic-like effects of nicotine in SB334867-pretreated mice (p < 0.05) (Fig. 1A). According to the pharmacological experiment, a significant interaction between nicotine treatment and genotype (F(1,11) = 9.12, p < 0.05) was revealed for the same parameter by two-way ANOVA. One-way ANOVA indicated the suppression of the anxiogenic-like effects of nicotine in preprohypocretin KO mice (p < 0.05) (Fig. 1B). In contrast, SB334867 administration did not modify the anxiolytic-like effects of nicotine (0.05 mg/kg, s.c.) in the elevated plus-maze (supplemental Fig. 2A, available at www.jneurosci.org as supplemental material). Other acute effects of nicotine such as hypolocomotion and antinociception were not either influenced by preadministration of SB334867 or preprohypocretin gene deletion (supplemental Fig. 3, available at www.jneurosci.org as supplemental material). Together, these data indicate that hypocretins selectively modulate the acute anxiogenic-like effects of nicotine.

To further evaluate the role of Hcrt neurons in the anxiogenic-like effects of nicotine, we studied the possible activation of these cells by using double label immunofluorescence of c-Fos with Hcrt-1 in the perifornical and dorsomedial hypothalamic areas (PFA/DMH) as well as in the lateral hypothalamus (LH). Nicotine (0.8 mg/kg, s.c.) induced a significant increase in the percentage of Hcrt-1 cells expressing c-Fos in preprohypocretin KO mice (Fig. 1C, D) in the PFA/DMH (p < 0.05), but no change was found in the LH (Fig. 1C). These data are in agreement with previous studies which suggest that Hcrt neurons located in the PFA/DMH respond to stressful events (Harris et al., 2005, 2007).

On the other hand, neurons expressing Hcrt-1 were not activated following the injection of a low dose of nicotine (0.05 mg/
kg, s.c.) which induces anxiolytic-like effects (supplemental Fig. 2B, available at www.jneurosci.org as supplemental material). This result is consistent with the behavioral study (supplemental Fig. 2A, available at www.jneurosci.org as supplemental material), and corroborates the lack of interaction between the Hcrt system and the anxiolytic-like effects of nicotine.

Hcrts modulate the activation of the paraventricular nucleus of the hypothalamus induced by the anxiogenic dose of nicotine

We next determined the brain areas involved in the anxiogenic-like effects of nicotine (Singewald et al., 2003; Hsu et al., 2007) and the possible role of Hcrt transmission in this effect by using immunofluorescence of c-Fos, an immediate-early gene used as a functional anatomical marker of cellular activation (Kovács, 2008). Acute nicotine injection (0.8 mg/kg, s.c.) induced an increase of c-Fos expression in the paraventricular nucleus of the hypothalamus (PVN) (Fig. 2A, B), and in the paraventricular nucleus of the thalamus (PVT) (supplemental Fig. 4, available at www.jneurosci.org as supplemental material). No increase in c-Fos expression was observed in other brain areas analyzed such as the central nucleus of the amygdala, cingulate cortex, medial and lateral septum, striatum, the bed nucleus of the stria terminalis and nucleus accumbens (supplemental Fig. 4, available at www.jneurosci.org as supplemental material). The previous administration of SB334867 or preprohypocretin gene deletion prevented the activation of the PVN induced by nicotine (Fig. 2A–D). In the pharmacological approach, two-way ANOVA showed a significant interaction between SB334867 pretreatment and nicotine treatment ($F_{1,16} = 16.95, p < 0.01$). One-way ANOVA revealed a blockade of nicotine activation of the PVN due to SB334867 pretreatment ($p < 0.01$) (Fig. 2A, C). In the genetic approach, two-way ANOVA also showed a significant interaction between genotype and nicotine treatment ($F_{1,8} = 27.23, p < 0.01$). An abolishment of c-Fos expression induced by nicotine in the PVN of preprohypocretin deficient mice was revealed by one-way ANOVA ($p < 0.01$) (Fig. 2B, D).

Again, the administration of the low dose of nicotine (0.05 mg/kg, s.c.) that produces anxiolytic-like effects did not increase the expression of c-Fos in the PVN (supplemental Fig. 2C, available at www.jneurosci.org as supplemental material), suggesting that this brain area is not involved in nicotine anxiolytic-like effects.

Nicotine-induced activation of CRF and AVP-expressing neurons located in the PVN is dependent on Hcrt-1

CRF- and AVP-expressing neurons are the most important cell types involved in the regulation of anxiety and stress responses within the PVN (Lightman, 2008; Landgraf, 2005). Therefore, we asked whether these neurons located in the PVN were activated following the injection of nicotine (0.8 mg/kg, s.c.) and the possible modulation of this effect by the Hcrt-1. Acute nicotine treatment induced an increase of c-Fos expression in both CRF- and AVP-expressing neurons (Fig. 3A, B) (supplemental Fig. 5, available at www.jneurosci.org as supplemental material for representative images), and SB334867 pretreatment prevented this activation. Thus, two-way ANOVA showed a significant interaction between SB334867 pretreatment and nicotine treatment ($F_{1,16} = 37.00, p < 0.01$ and $F_{1,8} = 14.07, p < 0.01$), for CRF and AVP experiments respectively. One-way ANOVA revealed a blockade of the activation of CRF ($p < 0.01$) and AVP ($p < 0.05$) neurons due to SB334867 pretreatment (Fig. 3A, B). On the contrary, the administration of a low dose of nicotine (0.05 mg/kg) was not effective to enhance the percentage of c-Fos-positive CRF (saline: 26.23 ± 6.14%; nicotine: 22.17 ± 6.64%) and AVP (saline: 21.26 ± 1.07%; nicotine: 18.68 ± 2.01%) neurons of the PVN. These data indicate that Hcrt-1 is necessary for CRF- and AVP-expressing cell activation in the PVN after nicotine (0.8 mg/kg, s.c.) treatment. We next investigated whether these neurons expressed Hcrt-1 by using double label immunofluorescence. As shown in Figure 3, C and D, Hcrt-1 is expressed by both neuronal types within the PVN.

Together, our results suggest that Hcrts participate in the acute anxiogenic-like effects of nicotine. This behavioral re-
response is associated to a stimulation of CRF and AVP neurons in the PVN that is dependent on Hcrt transmission. However, the possible involvement of other cellular types of the PVN in the modulation that Hcrts exert on this nicotine behavioral response cannot be excluded. Thus, the anxiogenic-like effects of nicotine were not blocked by the pretreatment with the CRF1 receptor antagonist antalarmin (supplemental Fig. 6, available at www.jneurosci.org as supplemental material). Thus, the total number of animals pretreated with vehicle or SB334867 (5 mg/kg, i.p.) acquired the operant behavior. The mean number of days needed to achieve the acquisition criteria was 5.70 ± 0.42 for vehicle-pretreated mice and 5.67 ± 0.69 for SB334867-pretreated animals. In addition, the breaking point in the progressive ratio schedule of reinforcement was similar in both groups of animals (vehicle-pretreated mice: 69 ± 7.37; SB334867-pretreated mice: 83.2 ± 18.09).

The Hcrt-1 antagonist SB334867, but not the CRF1 receptor antagonist antalarmin, blocks the reinstatement of nicotine-seeking induced by Hcrt-1
We assessed the ability of Hcrt-1 (0.75 nmol/1 μl, i.c.v.) to reinstate nicotine-seeking behavior and the possible role of Hcrt-1 and CRF1 receptor in this effect. For the statistical analysis, mice were divided in 3 different groups depending on the treatment preceding the Hcrt-1 infusion: vehicle, SB334867 5 mg/kg or antalarmin 30 mg/kg. Statistical analysis is summarized in Tables 1 and 2. Tests for reinstatement were conducted under the same conditions used in the extinction phase. The first day after reaching the extinction criterion, mice were infused with an intracere-
or antalarmin 30 mg/kg. The animals that received the intracerebroventricular Hcrt-1 infusion preceded by vehicle, SB334867 5 mg/kg, reinstated the behavior after footshock exposure similarly to those pretreated with vehicle (Fig. 6), suggesting that Hcrt-1 does not participate in footshock stress-induced reinstatement of nicotine-seeking behavior. A higher dose of this antagonist was not used due to the decrease of locomotor activity observed at the dose of 15 mg/kg in C57BL/6j mice, which could difficult the interpretation of the data (supplemental Fig. 8, available at www.jneurosci.org as supplemental material). On the contrary to SB334867, antalarmin blocked footshock stress-induced reinstatement of nicotine-seeking (Fig. 6), suggesting an involvement of CRF1 receptor in this nicotine behavioral response.

Discussion

Our study demonstrates that Hcrts participate in the acute anxiogenic-like effects of nicotine. This behavioral response was associated to a stimulation of CRF and AVP neurons in the PVN that was dependent on Hcrt transmission. The possible involvement of other cellular types of the PVN in the modulation that Hcrts exert on the anxiogenic-like effects of nicotine cannot be ruled out since the single blockade of the CRF1 receptor is not sufficient to abolish this nicotine behavioral response. Moreover, we also show for the first time that Hcrt-1, likely via Hcrtr-1 activation, induces reinstatement of nicotine-seeking behavior. The mechanism by which Hcrt-1 induces reinstatement seems to be independent of the CRF system. Thus, the CRF1 receptor antagonist antalarmin did not block the effects of Hcrt-1 on reinstatement whereas the Hcrt-1 antagonist SB334867 did not modify the CRF-dependent footshock-induced reinstatement of nicotine-seeking.

Nicotine has been shown to produce anxiolytic- and anxiogenic-like responses depending on the dose used, and to activate the PVN and the HPA axis in rodents (Valentine et al., 1996; Loughlin et al., 2006; Lutfy et al., 2006; Shram et al., 2007). Low doses of nicotine usually induce anxiolytic-like effects whereas higher doses cause the opposite response in mice (Balerio et al., 2005). Our results demonstrate a correlation between the anxiogenic-like effects of nicotine and the consequent activation of CRF and AVP neurons in the PVN. Previous administration of the selective Hcrt-1 antagonist SB334867 or the deletion of preprohypocretin gene blocked the anxiogenic-like response of nicotine in the elevated plus-maze. This effect was less robust in the case of the mutant animals probably due to the mild hypolocomotion (supplemental Fig. 3B, available at www.jneurosci.org as supplemental material) shown by these mice. Furthermore, nicotine-induced c-Fos expression in the PVN was also completely reversed by SB334867 and in mice lacking the preprohypocretin gene. In agreement, the activation of CRF and AVP cells was also reduced by pretreatment with the Hcrt-1 antagonist. However, the anxiolytic-like effects of nicotine were not related to the activation of CRF and AVP neurons in the PVN. Hcrt-containing neurons are restricted to the lateral hypothalamus and their projections are widely distributed in the CNS.

Figure 4. Acquisition and extinction of nicotine self-administration behavior. A, B. Mean number of nose-poking responses in the active (●) and inactive (□) holes during nicotine self-administration training and extinction. The complete group of animals used in the different experiments of reinstatement is shown (n = 50). A. Mice were trained daily in 1 h sessions to obtain nicotine (85.5 μg/kg per infusion) during 10 d under a fixed ratio 1 schedule of reinforcement. B. The first 15 d of the extinction phase and the last 3 d achieving the extinction criterion (E1, E2, E3) are shown. Sessions were conducted daily and lasted for 1 h. Animals were no longer reinforced after an active nose-poke. Data are expressed as mean ± SEM, **p < 0.01 comparison between holes (one-way ANOVA).
related to Hcrt release in the PVN and that CRF and AVP cell stimulation is associated to this behavioral response. Indeed, we have observed an activation of Hcrt cells located in the PFA/DMH following the injection of the anxiogenic dose of nicotine. Thus, PFA/DMH Hcrt neurons respond to stressful events and might activate CRF systems (Harris et al., 2005, 2007). Moreover, a high dose of nicotine has been also previously reported to increase c-Fos expression in Hcrt neurons in rats (Pasumarthi et al., 2006). On the contrary, the injection of a low dose of nicotine which induces anxiolytic-like effects did not increase c-Fos expression in Hcrt neurons. Based on our pharmacological and biochemical data and the colocalization of Hcrt-1 with CRF and AVP neurons of the PVN reported here, Hcrt seems to be involved in the regulation of nicotine-induced anxiogenic-like effects. This location of Hcrt-1 confirms previous results obtained in rat brain (Bäckberg et al., 2002). The role for Hcrt transmission in acute nicotine effects seems to be specific for the

(Peyron et al., 1998). The PVN receives Hcrt fibers from the perifornical region of the hypothalamus (Peyron et al., 1998), and a depolarization of magnocellular neurons in the PVN is induced by Hcrt-1 (Shirasaka et al., 2004; Samson et al., 2002; Follwell and Ferguson, 2002). A specific activation of CRF cells in the parvocellular division of the PVN has been also reported after Hcrt-1 administration (Sakamoto et al., 2004). Reciprocally, the application of CRF to hypothalamic slices containing Hcrt neurons increases firing rate of these cells (Winsky-Sommerer et al., 2004). This result correlates with the lack of activation of hypocretinergic neurons observed in CRF1 receptor KO mice in response to acute stress (Winsky-Sommerer et al., 2004). Together, these studies indicate that the Hcrt system is a key component of the pathways contributing to CRF-mediated behaviors that occur in response to stressful situations (Winsky-Sommerer et al., 2005). Consistent with this notion, our data suggest that the acute anxiogenic-like effects of nicotine are

Table 1. Statistical values obtained by two-way ANOVA with repeated measures in the factors hole (active vs inactive) and experimental phase (acquisition, extinction, reinstatement) for each reinstatement condition

<table>
<thead>
<tr>
<th>Hole</th>
<th>F value</th>
<th>p value</th>
<th>Experimental phase</th>
<th>F value</th>
<th>p value</th>
<th>Interaction</th>
<th>F value</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle + hypocretin-1</td>
<td>$F_{(1,8)} = 101.802$</td>
<td>$&lt;0.001$</td>
<td>$F_{(2,24)} = 18.928$</td>
<td>$&lt;0.001$</td>
<td>$F_{(2,24)} = 22.109$</td>
<td>$&lt;0.001$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SB33467 5 mg/kg + hypocretin-1</td>
<td>$F_{(1,8)} = 6.428$</td>
<td>NS</td>
<td>$F_{(2,24)} = 6.493$</td>
<td>$&lt;0.05$</td>
<td>$F_{(2,24)} = 14.844$</td>
<td>$&lt;0.01$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antalarmin 30 mg/kg + hypocretin-1</td>
<td>$F_{(1,8)} = 45.678$</td>
<td>$&lt;0.01$</td>
<td>$F_{(2,24)} = 6.565$</td>
<td>$&lt;0.05$</td>
<td>$F_{(2,24)} = 13.111$</td>
<td>$&lt;0.01$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vehicle + footshock</td>
<td>$F_{(1,10)} = 55.275$</td>
<td>$&lt;0.001$</td>
<td>$F_{(2,26)} = 11.874$</td>
<td>$&lt;0.001$</td>
<td>$F_{(2,26)} = 18.209$</td>
<td>$&lt;0.001$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SB33467 5 mg/kg + footshock</td>
<td>$F_{(1,10)} = 8.331$</td>
<td>$&lt;0.05$</td>
<td>$F_{(2,26)} = 11.709$</td>
<td>$&lt;0.01$</td>
<td>$F_{(2,26)} = 4.615$</td>
<td>$&lt;0.05$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SB33467 10 mg/kg + footshock</td>
<td>$F_{(1,10)} = 18.071$</td>
<td>$&lt;0.01$</td>
<td>$F_{(2,26)} = 13.672$</td>
<td>$&lt;0.01$</td>
<td>$F_{(2,26)} = 4.304$</td>
<td>$&lt;0.05$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antalarmin 30 mg/kg + footshock</td>
<td>$F_{(1,10)} = 96.425$</td>
<td>$&lt;0.001$</td>
<td>$F_{(2,26)} = 12.671$</td>
<td>$&lt;0.01$</td>
<td>$F_{(2,26)} = 26.851$</td>
<td>$&lt;0.001$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Statistical values obtained by one-way ANOVA with repeated measures in the factors hole (active vs inactive) and experimental phase (acquisition, extinction, reinstatement) for each reinstatement condition

<table>
<thead>
<tr>
<th>Hole</th>
<th>F value</th>
<th>p value</th>
<th>Experimental phase</th>
<th>F value</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle + hypocretin-1</td>
<td>$F_{(1,8)} = 40.981$</td>
<td>$&lt;0.001$ Active</td>
<td>$F_{(2,24)} = 22.582$</td>
<td>$&lt;0.001$</td>
<td></td>
</tr>
<tr>
<td>Acquisition</td>
<td>$F_{(1,8)} = 3.573$</td>
<td>NS</td>
<td>$F_{(2,24)} = 1.854$</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Extinction</td>
<td>$F_{(1,8)} = 2.286$</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>$F_{(1,8)} = 46.952$</td>
<td>$&lt;0.001$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reinstatement</td>
<td>$F_{(1,8)} = 14.527$</td>
<td>$&lt;0.05$ Active</td>
<td>$F_{(2,24)} = 13.493$</td>
<td>$&lt;0.01$</td>
<td></td>
</tr>
<tr>
<td>Acquirtion</td>
<td>$F_{(1,8)} = 0.316$</td>
<td>NS</td>
<td>$F_{(2,24)} = 1.093$</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Extinction</td>
<td>$F_{(1,8)} = 0.231$</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>$F_{(1,8)} = 3.000$</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reinstatement</td>
<td>$F_{(1,8)} = 37.686$</td>
<td>$&lt;0.01$ Active</td>
<td>$F_{(2,24)} = 9.007$</td>
<td>$&lt;0.01$</td>
<td></td>
</tr>
<tr>
<td>Acquirtion</td>
<td>$F_{(1,8)} = 7.046$</td>
<td>NS</td>
<td>$F_{(2,24)} = 1.487$</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Extinction</td>
<td>$F_{(1,8)} = 0.648$</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>$F_{(1,8)} = 33.989$</td>
<td>$&lt;0.05$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vehicle + footshock</td>
<td>$F_{(1,10)} = 69.835$</td>
<td>$&lt;0.001$ Active</td>
<td>$F_{(2,26)} = 20.561$</td>
<td>$&lt;0.001$</td>
<td></td>
</tr>
<tr>
<td>Acquisition</td>
<td>$F_{(1,10)} = 0.021$</td>
<td>NS</td>
<td>$F_{(2,26)} = 4.140$</td>
<td>$&lt;0.05$</td>
<td></td>
</tr>
<tr>
<td>Extinction</td>
<td>$F_{(1,10)} = 16.369$</td>
<td>$&lt;0.01$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquirtion</td>
<td>$F_{(1,10)} = 24.400$</td>
<td>$&lt;0.01$ Active</td>
<td>$F_{(2,26)} = 12.330$</td>
<td>$&lt;0.01$</td>
<td></td>
</tr>
<tr>
<td>Extinction</td>
<td>$F_{(1,10)} = 13.900$</td>
<td>$&lt;0.05$ Inactive</td>
<td>$F_{(2,26)} = 5.648$</td>
<td>$&lt;0.05$</td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>$F_{(1,10)} = 1.327$</td>
<td>NS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reinstatement</td>
<td>$F_{(1,10)} = 46.952$</td>
<td>$&lt;0.001$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquirtion</td>
<td>$F_{(1,10)} = 18.157$</td>
<td>$&lt;0.01$ Active</td>
<td>$F_{(2,26)} = 9.241$</td>
<td>$&lt;0.01$</td>
<td></td>
</tr>
<tr>
<td>Extinction</td>
<td>$F_{(1,10)} = 14.611$</td>
<td>$&lt;0.01$ Inactive</td>
<td>$F_{(2,26)} = 11.882$</td>
<td>$&lt;0.01$</td>
<td></td>
</tr>
<tr>
<td>Reinstatement</td>
<td>$F_{(1,10)} = 8.392$</td>
<td>$&lt;0.05$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquirtion</td>
<td>$F_{(1,10)} = 62.701$</td>
<td>$&lt;0.01$ Active</td>
<td>$F_{(2,26)} = 19.355$</td>
<td>$&lt;0.001$</td>
<td></td>
</tr>
<tr>
<td>Extinction</td>
<td>$F_{(1,10)} = 247.353$</td>
<td>$&lt;0.001$ Inactive</td>
<td>$F_{(2,26)} = 0.823$</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Saline</td>
<td>$F_{(1,10)} = 21.250$</td>
<td>$&lt;0.01$</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
anxiogenic-like responses since the anxiolytic-like effects, hypolocomotion and antinociception induced by this drug were not modified by the previous administration of SB334867 or prepro-hypocretin gene deletion.

Stress exposure and other stimuli leading to nicotine relapse are crucial for the maintenance of nicotine addiction (Dravolina et al., 2007; Bilkei-Gorzo et al., 2008; Martín-García et al., 2009). We examined the ability of Hcrt-1 to induce reinstatement of previously extinguished nicotine-seeking behavior and, if so, whether the Hcrt-1 and the CRF1 receptor were involved in this mechanism. In addition, we evaluated the role of these receptors in the reinstatement of nicotine-seeking induced by stress. Intravenous nicotine-self administration was performed in freely moving naive mice that were not previously trained with any other rewarding stimulus unlike previous studies in this animal specie (Picciotto et al., 1998; Bilkei-Gorzo et al., 2008). This is an important issue since the reinforcing effects of nicotine are influenced by stress or the previous experience with food or other drugs (Thomsen and Caine, 2007), which makes the interpretation of these data difficult. Following the extinction period, the intracerebroventricular infusion of Hcrt-1 induced reinstatement of nicotine-seeking and this effect was abolished by the previous administration of SB334867, suggesting a selective involvement of Hcrt-1. In line with this finding, the intracerebroventricular and intraventral tegmental area (intra-VTA) administration of Hcrt-1 has been shown to restate extinguished cocaine-seeking in rats (Boutrel et al., 2005; Wang et al., 2009). The intra-VTA injection of Hcrt-1 also reinstates a previously extinguished conditioned place preference to morphine in rats (Harris et al., 2005). Interestingly, the Hcrt-1 antagonist SB334867 was not effective to block footshock stress-induced reinstatement of nicotine-seeking in the present study. Previous studies have described that footshock stress increases CRF expression in several brain areas (Funk et al., 2006), and causes release of CRF in the VTA (Wang et al., 2005), pointing to a role for extrahypothalamic CRF in stress-induced reinstatement of drug-seeking (Shalev et al., 2009). We found that the CRF1 receptor antagonist antalarmin blocked footshock-induced reinstatement of nicotine-seeking, in agreement with earlier studies performed in rats (Zislis et al., 2007; Bruijnzeel et al., 2009). Footshock-induced CRF release in the VTA produces glutamate and dendritic dopamine release in this brain area in rats with a previous history of cocaine intake, but not in cocaine-naive rats (Wang et al., 2005). This cocaine-induced neuroadaptation in the VTA appears to play an important role in stress-induced relapse (Wang et al., 2005). Hcrt peptides have also important effects in the VTA (Borgland et al., 2009) and Hcrt-1 signaling is involved in the formation of drug-dependent synaptic plasticity in this brain area (Borgland et al., 2006; Bonci and Borgland, 2009). A recent study has shown that the Hcrt-1 antagonist SB408124 blocks the reinstatement of cocaine-seeking, as well as glutamate and dopamine release in the VTA, induced by the intra-VTA perfusion of Hcrt-1 (Wang et al., 2009). Interestingly, footshock-induced cocaine reinstatement and associated neurotransmitter enhancement were not prevented by the intra-VTA perfusion of the Hcrt-1 antagonist (Wang et al., 2009). Furthermore, the CRF antagonist α-helical CRF did not modify the Hcrt-1 neurochemical and behavioral effects, while blocked similar responses induced by footshock (Wang et al., 2009). In agreement, we found that the pretreatment with the
CRF1 receptor antagonist antalarmin at a dose that blocks footshock stress-induced reinstatement of nicotine-seeking had no effects on the reinstatement induced by Hcrt-1. Furthermore, a previous study also showed that the CRF antagonist D-Phe-CRH12–41 attenuated, but not abolished, Hcrt-1-induced reinstatement of cocaine-seeking (Boutrel et al., 2005). Therefore, it is tempting to hypothesize that, similar to the effects of cocaine, the reinstatement of nicotine-seeking induced by Hcrt-1 and by CRF-dependent stress could be mediated by independent mechanisms leading both to similar final biochemical and behavioral changes. In contrast with this hypothesis, the systemic injection of the Hcrt1-antagonist SB334867 inhibits yohimbine-induced reinstatement of ethanol-seeking (Richards et al., 2008) and footshock-induced cocaine-seeking in rats (Boutrel et al., 2005), although the high dose of this antagonist used in the last study could induce nonspecific behavioral impairments such as abnormal posture and immobility (Nair et al., 2008). Future research is needed to elucidate other possible mechanisms underlying reinstatement of nicotine-seeking induced by Hcrt-1. In addition, further investigation will be also necessary to explore the potential participation of Hcrt transmission in the other two modalities involved in nicotine relapse, i.e., nicotine-associated cues and reexposure to nicotine.

In conclusion, our study suggests that Hcrt peptides play a crucial role in the modulation of the acute anxiogenic-like effects of nicotine and the neurobiological processes driving to relapse to nicotine-seeking. The modulation that Hcrt peptides exert on nicotine anxiogenic-like effects is associated to an activation of CRF and AVP neurons in the PVN. We also show that the mechanism by which Hcrt-1 induces nicotine-seeking reinstatement does not depend on CRF. Instead, CRF mediates the reinstatement of nicotine-seeking induced by stress. Therefore, we reveal that Hcrt and CRF modulate nicotine relapse through independent, but complementary mechanisms. This could have important therapeutic implications since a combination therapy of Hcrt and CRF antagonists could offer strong efficacy to avoid relapse to drug-seeking compared with a single-target approach, as recently suggested (Borgland et al., 2009). The identification of hypothalamic Hcrts as a new neuromodulatory system involved in reinstatement of nicotine-seeking could improve the therapeutic approaches leading to treat addiction since the prevention of relapse after smoking cessation is still the main need uncovered by the currently available treatments.

References